Of note, non-small cell lung cancer (NSCLC) patients treated with Chk1 inhibitors reportedly showed partial responses in Phase 1 trials (Calvo et al., 2014; Sausville et al., 2014). Here, CHEK1 is linked to non-small cell lung carcinoma.